tbuckley/cabot-search huggingface dataset:
Encapsulated microRNA by gemcitabine prodrug for cancer treatment
Authors: Hai-Tao Zhang, Jing Sun, Yi Yan, Shi-He Cui, Hao Wang, Cheng-Han Wang, Chong Qiu, Xin Chen, Jin-Song Ding, Hong-Gang Qian, Jian-Cheng Wang, Qiang Zhang
Journal: Journal of Controlled Release (2019)
Are Racial Disparities in Acute Myeloid Leukemia (AML) Clinical Trial Enrollment Associated with Comorbidities and/or Organ Dysfunction?
Authors: Abby Statler, Brian P. Hobbs, Tomas Radivoyevitch, Sudipto Mukherjee, Kimberly Bell, Anjali S. Advani, Aaron T. Gerds, Aziz Nazha, Bhumika J. Patel, Hetty E. Carraway, Mikkael A. Sekeres
Journal: Blood (2019)
Heart failure after treatment for breast cancer
Authors: Naomi B. Boekel, Fran K. Duane, Judy N. Jacobse, Michael Hauptmann, Michael Schaapveld, Gabe S. Sonke, Jourik A. Gietema, Maartje J. Hooning, Caroline M. Seynaeve, Angela H.E.M. Maas, Sarah C. Darby, Berthe M.P. Aleman, Carolyn W. Taylor, Flora E. van Leeuwen
Journal: European Journal of Heart Failure (2019)
Detailed Functional Characterization of Splenic Marginal Zone Lymphoma: Uncovering Links between the Epigenetic and the Signaling Machinery
Authors: Stavroula Ntoufa, Maria Gounari, Nikos Papakonstantinou, Despoina Binou, Ioannis Tyritidis, Theodora Stivarou, Ioannis Sarrigeorgiou, Anastasia Iatrou, Niki Stavroyianni, Achilles Anagnostopoulos, Peggy Lymberi, Kostas Stamatopoulos
Journal: Blood (2019)
Diverse pathogenetic roles of SOX genes in acute myeloid leukaemia and their therapeutic implications
Authors: Richard K.C. Leung, Ho Ching Leung, Anskar Y.H. Leung
Journal: Seminars in Cancer Biology (2019)

Acute myeloid leukaemia (AML) is a heterogeneous group of diseases with diverse pathogenetic pathways. When treated uniformly with conventional chemotherapy and allogeneic haematopoietic stem cell transplantation (HSCT), it showed variable clinical outcome and prognosis. Members of the SOX [Sry-related high-mobility group (HMG) box] gene family are involved in diverse embryonic and oncogenic processes. The roles of SOX genes in AML are not entirely clear but emerging evidence, including that arising from studies in solid-cancers, showed that SOX genes can function as tumour suppressors or oncogenes and may be involved in key pathogenetic pathways in AML involving C/EBPα mutations, activation of β-catenin/Wnt and Hedgehog pathways and aberrant TP53 signals. Recent data based on genomics and proteomics have identified key interactions between SOX genes and partnering proteins of pathogenetic significance. The observations illustrated the principles and feasibilities of developing lead molecules of potential therapeutic values. Studying the diverse pathogenetic roles of SOX genes in AML may shed lights to the heterogeneity of AML and generate information that can be translated into novel therapeutic strategies.
INNV-04. IDH MUTATION PREDICTION IN GLIOMA: A MULTIMODAL APPROACH
Authors: Tareq Juratli, Amir Zolal, Sebastian Stasik, Mirko Pietzsch, Graeme Eisenhofer, Jennifer Linn, Gabriele Schackert, Christian Thiede, Dietmar Krex, Annett Werner
Journal: Neuro-Oncology (2019)

Abstract OBJECTIVE Non-invasive and accurate diagnostic techniques to detect isocitrate dehydrogenase (IDH) mutant glioma may have great potential in routine clinical practice. With this in mind, we performed a multimodal diagnostic approach to predict the IDH mutation status in newly diagnosed gliomas using: 2-Hydroxyglutarate (2HG) single-voxel spectroscopy (SVS), IDH-mutant cell-free tumor-derived DNA (tDNA) in the CSF, in addition to 2HG (D- and L- forms) concentration measurement in the CSF. METHODS 2HG MR spectroscopy was obtained in 18 patients with a newly diagnosed IDH-mutant glioma. The IDH1/2 mutation status was determined using next generation sequencing in the glioma tissue and in the CSF-tDNA (n=55). In addition, in a subset of patients (n=15), 2HG concentrations were measured in the CSF using liquid chromatography-tandem mass spectrometry (LCMS). Ratios of D-and L-2HG were used to evaluate differences in 2HG accumulation in tumors. RESULTS IDH mutations were correctly predicted using the 2HG spectroscopy with 93.3% sensitivity (17/18, 95% CI, 85.3–100%) and 100% specificity (18/18, 95% CI, 88.6–100%). The IDH mutation in the CSF-tDNA was successfully detected with 100% specificity (95% CI, 87.6–100%) and 73.3% sensitivity (95% CI, 65.6–88.3%). The range of the IDH mutation variant allele frequency (VAF) in the CSF-tDNA was 1.53- 47.9%. 2HG detection in the CSF revealed higher sensitivity (100%) and specificity (100%) in a small subset of patients (n = 7). The D-2HG/L-2HG ratios in IDH-mutant cases varied between 1.2 – 13.8, compared with 0.1 – 0.5 in IDH wild-type gliomas. CONCLUSION Our findings suggest that 2HG spectroscopy and 2HG detection in the CSF are two reliable methods in IDH mutation prediction in gliomas. On the other hand, the sensitivity of genomic IDH mutation detection in the CSF-tDNA was lower when compared with 2HG detection. Further studies are needed to complement the findings of our exploratory analysis.
Personal use of drug samples by physicians and office staff
Authors: H. J. Mehta
Journal: JAMA (1997)

To the Editor.  —I take serious offense regarding the article by Dr Westfall and colleagues1on the personal use of drug samples by physicians and office staff. In our office we use many samples, and 90% or more are for the benefit of the patients. Samples are a great boon to needy patients, and they are hardly used by our office staff and physicians. The Food and Drug Administration and the government will definitely look at this most unscientific report very negatively. This is only going to hurt the needy patients who get serious benefit from such samples offered by the pharmaceutical companies.
Supplementation With Vitamin D and Omega-3 Fatty Acids and Incidence of Heart Failure Hospitalization
Authors: Luc Djoussé, Nancy R. Cook, Eunjung Kim, Vijaykumar Bodar, Joseph Walter, Vadim Bubes, Heike Luttmann-Gibson, Samia Mora, Jacob Joseph, I-Min Lee, Christine M. Albert, Julie E. Buring, J. Michael Gaziano, JoAnn E. Manson
Journal: Circulation (2019)
Association of Postoperative Infection With Risk of Long-term Infection and Mortality
Authors: William J. O’Brien, Kalpana Gupta, Kamal M. F. Itani
Journal: JAMA Surgery (2019)

Surgical site infection has been shown to decrease survival in veterans by up to 42%. The association of 30-day postoperative infections with long-term infections in the overall surgical population remains unknown.To determine whether exposure to 30-day postoperative infection is associated with increased incidence of infection and mortality during postoperative days 31 to 365.In this retrospective observational cohort study, veterans undergoing major surgery through the Veterans Health Administration from January 2008 to December 2015 were included. Stabilized inverse probability of treatment weighting was used to balance baseline characteristics of the control and exposure groups. Cox proportional hazards regression was used to estimate hazard ratios of long-term infection and mortality. Data were analyzed from September 2018 to May 2019.Any 30-day postoperative infection (exposure group) vs no 30-day infection (control group).Number of days between index surgery and the occurrence of death or the patient's first infection during postoperative days 31 to 365. Patients who died before having a long-term infection were censored for the infection outcome.Of the 659 486 included patients, 604 534 (91.7%) were male, and the mean (SD) age was 59.7 (13.6) years. Among these patients, 23 815 (3.6%) had a 30-day infection, 43 796 (6.6%) had a long-term infection, and 24 810 (3.8%) died during follow-up. The most frequent 30-day infections were surgical site infection (9574 [40.2%]), urinary tract infection (6545 [27.5%]), pneumonia (3515 [14.8%]), and bloodstream infection (1906 [8.0%]). Long-term infection types included urinary tract infection (21 420 [48.7%]), skin and soft tissue infection (14 348 [32.6%]), bloodstream infection (3862 [8.8%]), and pneumonia (2543 [5.8%]). Patients in the exposure group had a higher observed incidence of long-term infection (5187 of 23 815 [21.8%]) and mortality (3067 of 23 815 [12.9%]) compared with those without 30-day infection (38 789 of 635 671 [6.1%] and 21 743 of 635 671 [3.4%], respectively). The estimated hazard ratio for long-term infection was 3.17 (95% CI, 3.05-3.28) and for mortality was 1.89 (95% CI, 1.79-1.99).At any given point during the follow-up period, patients with 30-day postoperative infection had a 3.2-fold higher risk of 1-year infection and a 1.9-fold higher risk of mortality compared with those who had no 30-day infection. Cost-benefit calculations for surgical infection prevention programs should include the increased risk and costs of long-term infection and death. Preventive efforts in the first 30 days postoperatively may improve long-term patient outcomes.
Myeloma Heterogeneity within Its Complex Immune Ecosystem
Authors: Jana Jakubikova, Danka Cholujova, Gabor Beke, Zachary R Hunter, Teru Hideshima, Merav Leiba, Krzysztof Jamroziak, Paul G. Richardson, Eftathios Kastritis, David M. Dorfman, Kenneth C. Anderson
Journal: Blood (2019)
Allele-Specific Expression of GATA2 in AML with CEBPA Biallelic Mutations
Authors: Roger Mulet-Lazaro, Stanley van Herk, Claudia Erpelinck-Verschueren, Mathijs A. Sanders, Eric Bindels, Peter Valk, Michael Rehli, Claudia Gebhard, Ruud Delwel, B.J. Wouters
Journal: Blood (2019)
Targeting AML: The Development of Two Functionally and Mechanistically Distinct Classes of Cereblon-Mediated Protein Homeostatic Modulators
Authors: Aparajita Hoskote Chourasia, Leah Fung, Brooke McElwee, Normand Richard, Imelda Lam, Eduardo Torres, Paul Erdman, Robert Sullivan, David Hecht, Kyle WH Chan, Frank Mercurio, David I Stirling
Journal: Blood (2019)
Autologous Stem Cell Transplantation in Favorable Acute Myeloid Leukemia Is Associated with a Better Long-Term Prognosis: a Single Center Experience
Authors: Ofrat Beyar-Katz, Israel Henig, Dana Yehudai, Nov Yuval, Riva Fineman, Nuhad Haddad, Yishai Ofran, Jacob M. Rowe, Tsila Zuckerman
Journal: Blood (2016)
Patient Derived Xenografts (PDX) Recapitulate Ruxolitinib Clinical Trial Responses and Identify a Novel Combination Therapy for Chronic Myelomonocytic Leukemia (CMML)
Authors: Hannah Newman, Anthony M. Hunter, Christopher Letson, Amy E. DeZern, Maria E Balasis, William Dominguez-Viqueira, Alexis Vedder, Traci Kruer, Jeffrey E. Lancet, Alan F. List, Gail J. Roboz, David P. Steensma, Mikkael A. Sekeres, Rami S. Komrokji, Eric Padron
Journal: Blood (2019)
AML-CM Score Predicts Prognosis in Hemato-Geriatric Patients with New-Onset Acute Myeloid Leukemia (AML) Who Receive Hypomethylating Agents (HMA)
Authors: Giovanni Marconi, Roberta di Nicola, Chiara Sartor, Mariachiara Abbenante, Jacopo Nanni, Gianluca Cristiano, Sarah Parisi, Carmen Baldazzi, Maria Chiara Fontana, Lorenza Bandini, Emanuela Ottaviani, Nicoletta Testoni, Giovanni Martinelli, Michele Baccarani, Cristina Papayannidis, Stefania Paolini, Michele Cavo, Antonio Curti
Journal: Blood (2019)
Outcome of Repeated Vaccination to Hepatitis B Virus in Patients Failing to Respond to Vaccination Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT): If at First You Don't Succeed, Try Try Again
Authors: Reem A Shalabi, Michelle A Borg, Thomas E Hughes, Tracey Walsh-Chocolaad, Rodica Ciurea, Lisa Cook, Tatyana Worthy, Kristen Gunn, Brian Wells, Georg Aue, Xin Tian, Richard W. Childs
Journal: Blood (2019)
Lentiviral Gene Therapy with Low Dose Busulfan for Infants with X-SCID Results in the Development of a Functional Normal Immune System: Interim Results of an Ongoing Phase I/II Clinical Study
Authors: Ewelina Mamcarz, Sheng Zhou, Timothy Lockey, Shannon Boi, Yan Koon-Kiu, Shane Cross, Guolian Kang, Zhijun Ma, Jose Marcos Condori, Jolanta Dowdy, Jean-Yves Metais, Deanna Langfitt, Brandon Triplett, Chen Li, Xiwen Zhao, Gabriela Maron, Sneha Suresh, Juan Carlos Aldave Becerra, Joseph Church, Elif Dokmeci, James T Love, Hedi van der Watt, Ana C da Matta Ain, Christa Krupski, Jiyang Yu, Lance E. Palmer, William Janssen, Suk See De Ravin, Mitchell J. Weiss, Benjamin Youngblood, Janel R Long-Boyle, Michael M Meagher, Harry L. Malech, Jennifer Puck, Morton J Cowan, Stephen Gottschalk
Journal: Blood (2019)
Sex Differences in Faculty Rank and Leadership Positions Amongst Hematologists and Oncologists in United States: A Cross-Sectional Study
Authors: Irbaz Riaz, Rabbia Siddiqi, Umar Zahid, Urshila Durani, Kaneez Fatima, Qurat Ul Ain Riaz Sipra, Ammad Raina, Muhammad Zain Farooq, Alanna Chamberlain, Zhen Wang, Ronald S. Go, Faisal Khosa, Ariela L. Marshall
Journal: Blood (2019)
Management of Major Surgical Procedures in Patients with Hemophilia: A Single-Center Experience of 49 Procedures
Authors: Veysel Suzan, Nurgul Ozgur Yurttas, Ahmet Emre Eskazan, Deniz Ozmen, Dilek Keskin, Sevil Sadri, Selin Berk, Isil Erdogan, Tugrul Elverdi, Ayse Salihoglu, Muhlis Cem Ar, Zafer Baslar
Journal: Blood (2019)
Randomized Phase 2 Zanubrutinib (BGB-3111) + Obinutuzumab Vs Obinutuzumab Monotherapy in Patients with Relapsed/Refractory Follicular Lymphoma (R/R FL)
Authors: Nathan H. Fowler, Judith Trotman, Rebecca Auer, Christopher R. Flowers, William F. Reed, Elena Ivanova, Jane Huang, Pier Luigi Zinzani
Journal: Blood (2019)
Allogeneic Hematopoietic Cell Transplantation (AHCT) in Post Infusion Cyclophosphamide (PIC) Era: The Switch from Anti-Thymocyte Globulin (ATG) to PIC for Graft Versus Host Disease (GVHD) Prophylaxis in AHCT from Alternative Donors
Authors: Deniz Goren Sahin, Nurcan Özçelik, Tülay E Özçeli̇k, Mutlu Arat
Journal: Blood (2019)
A Mutation Pentad Defined Outcome of De Novo and Cytogenetically Normal Acute Myeloid Leukaemia in Young Adults
Authors: Sze Pui Tsui, Ip HW Alvin, Chunxiao Zhang, Tommy W.F. Tang, CH Lin, Arthur Cheung, Grace Cheng, Jason Chi Chiu So, S.Y. Leung, Tommy CH Au, Edmond S. K. Ma, Chris T.L. Chan, Margaret Ng, Kelvin CK Cheng, Kit Fai Wong, Lisa L.P. Siu, Sze Fai Yip, S.Y. Lin, Szeman June Lau, T.H. Luk, Harold K K Lee, Chi Kuen Lau, Bonnie Kho, Yok Lam Kwong, Asif Javed, Anskar Yu Hung Leung
Journal: Blood (2019)
The Protein Kinase C Inhibitor MS-553 for the Treatment of Chronic Lymphocytic Leukemia
Authors: Elizabeth M. Muhowski, Amy M. Lehman, Sean D. Reiff, Janani Ravikrishnan, Rose Mantel, Shrilekha Misra, Michael Niesman, Kai Zhang, James S. Blachly, Deepa Sampath, John C. Byrd, Jennifer Woyach
Journal: Blood (2019)
Biomarker Modulation By Mivebresib (ABBV-075) +/- Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia
Authors: Gautam M. Borthakur, Olatoyosi Odenike, Ibrahim Aldoss, David A. Rizzieri, Thomas Prebet, Dimple A. Modi, Rujuta Joshi, Beibei Hu, Yan Sun, Johannes E. Wolff, Brian A Jonas
Journal: Blood (2019)
Frailty-Adjusted Therapy in Transplant Non-Eligible Patients with Newly Diagnosed Multiple Myeloma (FiTNEss): A UK Myeloma Research Alliance Study, Myeloma XIV
Authors: David Cairns, Charlotte Pawlyn, Kara-Louise Royle, Phillip Best, Jenny Bird, Stella Bowcock, Kevin Boyd, Bryony Dawkins, Mark T Drayson, Rowena Henderson, Matthew Jenner, John R Jones, Martin F. Kaiser, Bhuvan Kishore, David Meads, Rebecca Mottram, Neil K Rabin, Roger G. Owen, Graham Jackson, Gordon Cook
Journal: Blood (2019)
Alkaline Diuresis for Aspirin Poisoning
Authors: A. F. Marston
Journal: BMJ (1964)

Doctors' Orders" SIR,-Like so many other doctors I have been appalled by the presentation and content of Doctors' Orders.It is based on the myth of the magical omniscience of the doctor in matters of " health " which belongs to the pre-scientific era of medicine.The advice given on diet implies acceptance of over-
Homologous Serum Jaundice
Authors: S. Truelove, L. Hogben
Journal: BMJ (1946)

<h3>Background</h3> Sedentary behaviour is an emerging cardiometabolic risk factor in young people. Little is known about how socioeconomic position (SEP) and sedentary behaviour are associated in children and adolescents. This study examines associations between SEP and sedentary behaviour in school-age children and adolescents. <h3>Methods</h3> The core sample comprised 3822 Health Survey for England 2008 participants aged 5–15 years with complete information on SEP (household income, head of household occupational social class and area deprivation) and self-reported sedentary time (television viewing and other sitting during non-school times). Accelerometer-measured total sedentary time was measured in a subsample (N=587). We examined multivariable associations between SEP (including a composite SEP score) and sedentary time using generalised linear models, adjusting for age, sex, body mass index, physical activity, accelerometer wear time and mutually adjusting for the other SEP indicators. <h3>Results</h3> Participants in the highest SEP category spent 16 min/day less (95% CI 6 to 25, p=0.003) watching TV than participants in the lowest SEP category; yet they spent 7 (2 to 16, p=0.010) and 17 (5 to 29, p&lt;0.000) min/day more in non-TV sitting and total (accelerometry-measured) sedentary time, respectively. Associations across individual SEP components varied in strength. Area deprivation was not associated with sedentary time. <h3>Conclusions</h3> Low SEP is linked with higher television times but with lower total (accelerometer-measured) sedentary time, and non-TV sitting during non-school time in children and adolescents. Associations between sedentary time and SEP differ by type of sedentary behaviour. TV viewing is not a good proxy for total sedentary time in children.
Cytogenetic Characteristics and Outcomes of Patients Receiving CTL019 CAR T Cell Therapy
Authors: Allison Barz Leahy, Kaitlin J. Stanley, Regina M. Myers, Amanda M. DiNofia, Lisa Wray, Susan R. Rheingold, Colleen Callahan, Diane Baniewicz, Amy E. Barry, Maria M. Patino, Stephen P. Hunger, Stephan Grupp, David M. Barrett, Shannon L. Maude
Journal: Blood (2019)
Computational Systems Biology Models for the Identification of Metabolic Vulnerabilities in Multiple Myeloma
Authors: Luis Vitores V. Valcárcel, Raquel Ordoñez, Iñigo Apaolaza, Ana Valcárcel, Leire Garate, Cem Meydan, Bruno Paiva, Ari M Melnick, Jesús San-Miguel, Francisco J. Planes, Xabier Agirre, Felipe Prosper
Journal: Blood (2019)
Hexabody-CD38, a Novel CD38 Antibody with a Hexamerization Enhancing Mutation, Demonstrates Enhanced Complement-Dependent Cytotoxicity and Shows Potent Anti-Tumor Activity in Preclinical Models of Hematological Malignancies
Authors: Bart ECG De Goeij, Maarten L Janmaat, Grietje Andringa, Laurens Kil, Berris Van Kessel, Kristine A. Frerichs, Andreas Lingnau, Andreas Freidig, Tuna Mutis, A. Kate Sasser, Esther C. W. Breij, Niels W. C. J. Van De Donk, Tahamtan Ahmadi, David Satijn
Journal: Blood (2019)
Consensus Statement on Sports-Related Concussions in Youth Sports Using a Modified Delphi Approach
Authors: Frederick P. Rivara, Robert Tennyson, Brianna Mills, Samuel R. Browd, Carolyn A. Emery, Gerald Gioia, Christopher C. Giza, Stanley Herring, Kathleen F. Janz, Cynthia LaBella, Tamara Valovich McLeod, William Meehan, Jon Patricios
Journal: JAMA Pediatrics (2019)

Given the importance of sports-related concussions among youth athletes, the rapid progress of research on this topic over the last decade, and the need to provide further guidance to youth athletes, their families, medical professionals, and athletic personnel and organizations, a panel of experts undertook a modified Delphi consensus process to summarize the current literature and provide recommendations regarding the prevention, assessment, and management of sports-related concussions for young athletes.A consensus panel of 11 experts was created to represent a broad spectrum of expertise in youth sports and concussions. The specific questions to be addressed were developed through an iterative process consisting of 3 rounds, and a review of the literature was conducted to identify research studies related to each question. The consensus panel used a modified Delphi process to reach consensus on the conclusions and recommendations for each question.In 3 Delphi consensus rounds, 7 questions were addressed by the consensus panel of 11 experts, and 26 recommendations for the prevention, assessment, and management of sports-related concussions among young athletes were developed. For many of the questions addressed in this consensus statement, limitations existed in the quantity and quality of the evidence available to develop specific recommendations for youth sports stakeholders.
Plasma Levels of Histone-DNA Complex and Cell-Free DNA Predict Mortality in Patients with Immune Thrombotic Thrombocytopenic Purpura
Authors: Jingrui (Jean) Sui, Konstantine Halkidis, Nicole K. Kocher, Lance A. Williams, Radhika Gangaraju, Bryan K. Guillory, Marisa B. Marques, Wenjing Cao, X. Long Zheng
Journal: Blood (2019)
Updated Phase 1 Results of a First-in-Human Open-Label Study of Lcar-B38M, a Structurally Differentiated Chimeric Antigen Receptor T (CAR-T) Cell Therapy Targeting B-Cell Maturation Antigen (Bcma)
Authors: Lijuan Chen, Jie Xu, Weijun Fu, Shiwei Jin, Shuangshuang Yang, Sun Yan, Wen Wu, Yuanfang Liu, Wu Zhang, Xiangqin Weng, Yan Wang, Jin WANG, Xiaoyi Ding, Biao Li, Jiang Zhu, Zhu Chen, Frank Xiao-Hu Fan, Jianyong Li, Jian Hou, Sai-Juan Chen, Jian-Qing Mi
Journal: Blood (2019)
RTHP-07. CYBERKNIFE HYPOFRACTIONATED STEREOTACTIC RADIOTHERAPY FOR THE PATIENTS OF RECURRENT GLIOBLASTOMA WITH BEVACIZUMAB TREATMENT FAILURE
Authors: Yusuke Tabei, Kengo Sato, Shunsuke Ichi
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND The prognosis for patients with recurrent glioblastoma after Bevacizumab (Bev) treatment is extremely poor. No effective treatment has been established. PURPOSE We retrospectively investigated the efficacy and safety of hypofractionated stereotactic radiotherapy with Cyberknife (CK-HSRT) for recurrent glioblastoma after Bev treatment in our institution. METHODS GTV (Gross tumor volume) was set in the FLAIR abnormal high signal area that resulted in the contrast lesion and invasive recurrence, and PTV (Planning target volume) = GTV + 2 mm. As aimed CK dose,30 Gray(Gy) in 5 fraction was performed on PTV. Bev(10mg/kg biweekly) was continued after CK. The case background, treatment effect, survival and adverse events were investigated for 21 cases from January 2013 to the end of May 2018. RESULTS The median age was 69 (range;31–85) years, and The D95% marginal dose was 27.5 (23–35) Gy in 5 (3–8) divisions. Median PTV was 112 (2–305) ml. The median time to progression after CK was 3.9 months, and the median overall survival after CK was 10.9 months. Early treatment-related adverse events included hair loss in the irradiated area, seizures, headache, nausea and vomiting. As late treatment-related adverse events, symptomatic cerebral radiation necrosis was not observed, but 2 cases of symptomatic cerebral infarction and a case of cerebral hemorrhage were observed. All cases were treated conservatively. CONCLUSION CK-HSRT may be well tolerated and effective as a salvage treatment for the patients with recurrent glioblastoma after Bev.
The cholesterol controversy.
Authors: T. Winder
Journal: BMJ (1992)

given them.This is patently not true.The details of the multiple risk factor intervention trial show that hydrochlorothiazide (the diuretic used long term in the Finnish study) was stopped because of an adverse effect on mortality.In the Finnish study the overall use of antihypertensive drugs in terms of patient exposure was far greater than exposure to hypolipidaemic drugs: what is sauce for the goose is sauce for the gander.It is important that the correct lessons are learnt from the Finnish study about the prevention of coronary heart disease.5We believe that readers have been done a disservice by Oliver's editorial.
The SF3b Splicing Complex Regulates DNA Damage Response in Acute Lymphoblastic Leukemia
Authors: Shalini Sankar, Miriam Guillen Navarro, Frida Ponthan, Simon Bomken, Sirintra Nakjang, Vasily Grinev, Hesta McNeill, Michel C Zwaan, Josef Vormoor, Ronald W. Stam, Olaf Heidenreich
Journal: Blood (2019)